Skip to content

Effect of intraoperative remimazolam on postoperative delirium in older cancer patients undergoing major oncologic surgery

Effect of intraoperative remimazolam on postoperative delirium in older cancer patients undergoing major oncologic surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122767
Enrollment
Unknown
Registered
2026-04-17
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Intervention group:remimazolam

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age = 60 years; 2.Clinically or radiologically diagnosed with a malignant solid organ tumor; 3.Planning to undergo elective radical oncologic surgery (including thoracic, gastrointestinal, gynecological, urological, hepatobiliary, head and neck, breast, and orthopedic tumor surgery) under general anesthesia or combined anesthesia (general plus regional anesthesia), with an expected surgical duration of =2 hours and a postoperative hospital stay of at least 3 days. 4.Willing to participate and provide written informed consent for the study;

Exclusion criteria

Exclusion criteria: 1.Refusal or inability to provide written informed consent for study participation; 2.Preoperative delirium or dementia; 3.Blindness, deafness, or language disorder precluding effective communication; 4.History of schizophrenia, epilepsy, or Parkinson's disease prior to surgery; 5.Acute or subacute cerebral infarction, lacunar infarction, encephalomalacia secondary to prior intracerebral hemorrhage, or history of neurosurgery; 6.Intracranial space-occupying lesion (primary or metastatic); 7.Renal failure requiring dialysis, or hepatic failure with Child-Pugh score >5; 8.Known allergy to remimazolam;

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium within 7 days;

Secondary

MeasureTime frame
Postoperative hospital length of stay;All-cause mortality within 30 days;Incidence of postoperative complications (excluding delirium) within 30 days;Length of ICU stay;Duration of delirium;Incidence of severe postoperative delirium within 7 days;

Countries

China

Contacts

Public ContactXianzhang Zeng

Chongqing University Cancer Hospital

qwj0915@163.com+86 23 6507 5696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026